A display screen shows the brand fro Cigna Corp. on the ground on the New York Inventory Change (NYSE) in New York, U.S., July 16, 2019. REUTERS/Brendan McDermid
(Reuters) – Well being insurer Cigna Corp on Thursday introduced a brand new program that covers prices for costly gene therapies that may reduce out-of-pocket funds for purchasers.
Spark Therapeutics Inc and Novartis AG’s blindness remedy, Luxturna, and Novartis’ $2.1 million spinal muscular atrophy remedy, Zolgensma, would be the first two gene therapies included in this system, the corporate stated.
Reporting by Manojna Maddipatla in Bengaluru; Modifying by Anil D’Silva